SALT LAKE CITY, Jan. 29, 2015 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today provided an update on its strategic plan for the Company ... Consumer Electronics Net, 3 hours ago
BSD Medical Corporation (BSDM)'s Investor and Analyst Conference Call Transcript - InsiderMonkey.com, 1 week ago
BSD Medical's (BSDM) CEO Clint Carnell on Q1 2015 Results - Earnings Call Transcript - Seeking Alpha, 1 week ago
2 images for "bsdm"
s Editor BSD Medical (BSDM -16.7%) FQ1 results: Revenues: $0.8M (-38.5%); COGS: $0.5M (-16.7%); Operating Expenses: $2.4M (+9.1%); Net Loss: ($2M) (-33.3%); Loss Per Share: ($0.05) (-25.0%); Quick Assets: $6.2M (-23.5%); CF Ops: ($1.9M) (-2.2%). ...Seeking Alpha, 2 weeks ago BSD Medical EPS of -$0.05 Seeking Alpha, 2 weeks ago Insider Buying: Gerhard W. Sennewald Buys 46,000 Shares of BSD Medical Stock (BSDM) American Banking News, 2 months ago
this session New highs (259) outpacing new lows (187) Stocks that traded to 52 week highs: AAT, ACC, ADC, ADVS, ADXS, AEC, AEP, AET, AFFX, AIV, AKR, ALGT, ALK, ALKS, ALR, ANTM, APU, ARE, ATO, AUXL, AVB, AVIV, AWR, AXL, AYN, BAH, BBC, BBN, BBW, ...Live Trading News, 1 week ago
Depomed to Acquire U.S. Rights to NUCYNTA®, NUCYNTA® ER and NUCYNTA®; Amgen Presents New Data Supporting First-Line Use Of Vectibix®
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 15, 2015. Depomed Inc. (NASDAQ: DEPO) announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA ...BioMedReports, 1 week ago Actinium Initiates cGMP Manufacturing of Iomab-B for Phase 3 Clinical Trial; Celator® Announces Publication Phase 2 Data For CPX-351 BioMedReports, 2 weeks ago Repros Initiates Two Phase 2B Uterine Fibroid Studies; Intersect ENT Announces Enrollment of First Patient in Phase III Study BioMedReports, 1 month ago
on your WebpageAdd Widget >Get your members hooked!